Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation

This randomized, double-blinded, placebo-controlled trial examined genetic influences on treatment response to sustained-release bupropion for smoking cessation. Smokers of European ancestry (N=291), who were randomized to receive bupropion or placebo (12 weeks) plus counseling, were genotyped for t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nicotine & tobacco research 2007-08, Vol.9 (8), p.821-833
Hauptverfasser:	David, Sean P., Brown, Richard A., Papandonatos, George D., Kahler, Christopher W., Lloyd-Richardson, Elizabeth E., Munafò, Marcus R., Shields, Peter G., Lerman, Caryn, Strong, David, McCaffery, Jeanne, Niaura, Raymond
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aryl Hydrocarbon Hydroxylases - genetics Bupropion - therapeutic use Cytochrome P-450 CYP2B6 Dopamine Plasma Membrane Transport Proteins - genetics Dopamine Uptake Inhibitors - therapeutic use Double-Blind Method Female Humans Male Middle Aged Oxidoreductases, N-Demethylating - genetics Polymorphism, Genetic Receptors, Dopamine D2 - genetics Smoking - drug therapy Smoking - genetics Smoking Cessation - methods Tobacco Use Disorder - drug therapy Tobacco Use Disorder - genetics Treatment Outcome White People - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!